Structure Therapeutics Inc (GPCR)
30.10
-2.61
(-7.98%)
USD |
NASDAQ |
Nov 21, 16:00
30.10
0.00 (0.00%)
After-Hours: 20:00
Structure Therapeutics Enterprise Value: 808.26M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 808.26M |
| November 20, 2024 | 957.71M |
| November 19, 2024 | 961.72M |
| November 18, 2024 | 902.74M |
| November 15, 2024 | 1.041B |
| November 14, 2024 | 1.243B |
| November 13, 2024 | 1.167B |
| November 12, 2024 | 1.202B |
| November 11, 2024 | 1.301B |
| November 08, 2024 | 1.262B |
| November 07, 2024 | 1.281B |
| November 06, 2024 | 1.281B |
| November 05, 2024 | 1.335B |
| November 04, 2024 | 1.360B |
| November 01, 2024 | 1.440B |
| October 31, 2024 | 1.441B |
| October 30, 2024 | 1.252B |
| October 29, 2024 | 1.320B |
| October 28, 2024 | 1.228B |
| October 25, 2024 | 1.237B |
| October 24, 2024 | 1.229B |
| October 23, 2024 | 1.264B |
| October 22, 2024 | 1.341B |
| October 21, 2024 | 1.307B |
| October 18, 2024 | 1.346B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.353B |
| October 16, 2024 | 1.317B |
| October 15, 2024 | 1.163B |
| October 14, 2024 | 1.181B |
| October 11, 2024 | 1.279B |
| October 10, 2024 | 1.310B |
| October 09, 2024 | 1.391B |
| October 08, 2024 | 1.404B |
| October 07, 2024 | 1.397B |
| October 04, 2024 | 1.546B |
| October 03, 2024 | 1.506B |
| October 02, 2024 | 1.575B |
| October 01, 2024 | 1.500B |
| September 30, 2024 | 1.598B |
| September 27, 2024 | 1.461B |
| September 26, 2024 | 1.448B |
| September 25, 2024 | 1.472B |
| September 24, 2024 | 1.591B |
| September 23, 2024 | 1.495B |
| September 20, 2024 | 1.471B |
| September 19, 2024 | 1.289B |
| September 18, 2024 | 1.261B |
| September 17, 2024 | 1.272B |
| September 16, 2024 | 1.361B |
| September 13, 2024 | 1.409B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
620.89M
Minimum
May 18 2023
3.241B
Maximum
Oct 31 2023
1.405B
Average
1.284B
Median
Jul 26 2024
Enterprise Value Benchmarks
| Viking Therapeutics Inc | 4.823B |
| Eli Lilly and Co | 739.59B |
| Novo Nordisk AS | 453.33B |
| Pfizer Inc | 199.35B |
| Amgen Inc | 207.22B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -33.98M |
| Total Expenses (Quarterly) | 45.84M |
| EPS Diluted (Quarterly) | -0.60 |
| Earnings Yield | -7.28% |